HSPB5 reduced serum IL-6 levels in both the NZB/W F1 and endotoxemia mouse studies, as well as kidney IL-6 transcript levels in NZB/W F1 mice, possibly by modulating both splenic and peritoneal macrophages given the route of administration. The gene discussed is CRYAB; the disease is serum lipopolysaccharide activity.